Jun Yokota

Jun Yokota

Auto-generated profile, based on publicly available information

Jun Yokota

Affiliation National Cancer Center Research Institute (NCCRI), Tokyo, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
IMIrene Marchesi
Irene Marchesi
Christoph SchröderChristoph Schröder
Christoph Schröder
RSRonny Schmidt
Ronny Schmidt
JYJun Yokota
Jun Yokota
Luigi BagellaLuigi Bagella
Luigi Bagella
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance. Despite that several target-based approaches with potential therapeutic impact on SCLC have been identified, numerous targeted drugs have not been successful in providing improvements in cancer patients when used as single agents. A combination of targeted therapies could be a strategy to induce maximum lethal effects on cancer cells. As a starting point in the development of new drug combination strategies for the treatment of SCLC, we performed a mid-throughput screening assay by treating a panel of SCLC cell lines with BETi or AKi in combination with PARPi or EZH2i. We observed drug synergy between I-BET762 and Talazoparib, BETi and PARPi, respectively, in SCLC cells. Combinatorial efficacy was observed in MYCs-amplified and MYCs-wt SCLC cells over SCLC cells with impaired MYC signaling pathway or non-tumor cells. We indicate that drug synergy between I-BET762 and Talazoparib is associated with the attenuation HR-DSBR process and the downregulation of various players of DNA damage response by BET inhibition, such as CHEK2, PTEN, NBN, and FANCC. Our results provide a rationale for the development of new combinatorial strategies for the treatment of SCLC.

14 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LCLaia Coll
Laia Coll
VDVerónica Dávalos
Verónica Dávalos
DPDavid Piñeyro
David Piñeyro
MRMargalida Rosselló-Tortella
Margalida Rosselló-Tortella
ABAlberto Bueno-Costa
Alberto Bueno-Costa
MEManel Esteller
Manel Esteller
The alteration of RNA modification patterns is emerging as a common feature of human malignancies. If these changes affect key RNA molecules for mRNA translation, such as transfer RNA, they can have important consequences for cell transformation. TRIT1 is the enzyme responsible for the hypermodification of adenosine 37 in the anticodon region of human tRNAs containing serine and selenocysteine. Herein, we show that TRIT1 undergoes gene amplification-associated overexpression in cancer cell lines and primary samples of small-cell lung cancer. From growth and functional standpoints, the induced depletion of TRIT1 expression in amplified cells reduces their tumorigenic potential and downregulates the selenoprotein transcripts. We observed that TRIT1-amplified cells are sensitive to arsenic trioxide, a compound that regulates selenoproteins, whereas reduction of TRIT1 levels confers loss of sensitivity to the drug. Overall, our results indicate a role for TRIT1 as a small-cell lung cancer-relevant gene that, when undergoing gene amplification-associated activation, can be targeted with the differentiation agent arsenic trioxide.

16 September 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
JTJuan L. Trincado
Juan L. Trincado
MRMarina Reixachs-Solé
Marina Reixachs-Solé
JPJudith Pérez-Granado
Judith Pérez-Granado
TFTim Fugmann
Tim Fugmann
FSFerran Sanz
Ferran Sanz
EEEduardo Eyras
Eduardo Eyras
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. Using RNA sequencing and mass spectrometry for MHC-I associated proteins, ISOTOPE identified neoepitopes from tumor-specific splicing events that are potentially presented by MHC-I complexes. Analysis of multiple samples indicates that splicing alterations may affect the production of self-epitopes and generate more candidate neoepitopes than somatic mutations. Although there was no difference in the number of splicing-derived neoepitopes between responders and non-responders to immune therapy, higher MHC-I binding affinity was associated with a positive response. Our analyses highlight the diversity of the immunogenic impacts of tumor-specific splicing alterations and the importance of studying splicing alterations to fully characterize tumors in the context of immunotherapies. ISOTOPE is available athttps://github.com/comprna/ISOTOPE.

1 March 1998 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YTYoshio Tomizawa
Yoshio Tomizawa
JAJun Adachi
Jun Adachi
TKTakashi Kohno
Takashi Kohno
NYNaohito Yamaguchi
Naohito Yamaguchi
RSRyusei Saito
Ryusei Saito
JYJun Yokota
Jun Yokota
Background: To clarify genetic factors involved in the susceptibility to lung cancer, it is essential to identify families with lung cancer clustering and to characterize the mode of clustering. Since somatic mutations of the p53, RB and p16 genes occur frequently in lung cancer and the replication error phenotype is seen in a subset of lung cancer, it is possible that germ-line mutations of the p53, RB, p16 and mismatch repair genes influence the susceptibility to lung cancer. Methods: In this work, cases with familial clustering of lung cancer were selected from 1068 families with primary lung cancer cases in analogy with the criteria for hereditary non-polyposis colorectal cancer (HNPCC). Cases with Li-Fraumeni syndrome, familial retinoblastoma, familial melanoma and HNPCC were also searched among these 1068 families. Results: There were only four families (0.4%) in which more than three relatives were affected by lung cancer. Two successive generations were affected in 36 families (3.4%). Patients with lung cancer before the age of 50 were present in 165 families (15.5%). However, no family conformed to all three criteria. There was only one family with Li-Fraumeni syndrome and no family with familial retinoblastoma, familial melanoma and HNPCC. Conclusion: Familial aggregation of lung cancer is rare and germ-line mutations of the p53, RB, p16 and mismatch repair genes may not contribute greatly to susceptibility to lung cancer.


1 December 2001 in International Journal of Human Genetics
Verified
Journal Article
Closed access
MKMasao Kanamori
Masao Kanamori
ASAudrey H. Schnell
Audrey H. Schnell
MIManami Inoue
Manami Inoue
YYYoshitaka Yamamura
Yoshitaka Yamamura
YWYoujie Wang
Youjie Wang
Haruhiko SugimuraHaruhiko Sugimura
Haruhiko Sugimura
Though its incidence and mortality have declined, gastric cancer is still the most common type of cancer in Japan. The cause of gastric cancer appears to be both genetic and environmental, with the possibility that the differentiated (internal) type is more environmentally determined than the non-differentiated (diffuse) type. Prior to this study, no formal segregation analysis of gastric cancer in Japan has been performed. Segregation analysis of gastric cancer that allowed for variable age of onset was performed on 851 two-generational pedigrees ascertained via gastric cancer probands collected from the Hospital based Epidemiological Research Program in the Aichi region of Japan. Families were classified based on the proband’s histopathological classification of having either differentiated type or nondifferentiated type of cancer. A random no major effect hypothesis was rejected, as was a purely recessive or dominant hypothesis. The most parsimonious model was one of purely multifactorial inheritance with males having a higher susceptibility than females. Under a model where genotype influences age of onset, a dominant or recessive mode of inheritance with multifactorial effects also fitted the data. In addition, the analyses were performed separately for the differentiated type and the non-differentiated type and homogeneity was not rejected.